Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer : A Review
BACKGROUND: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.
CONCLUSION: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Current pharmacogenomics and personalized medicine - 15(2017), 2 vom: 01. Dez., Seite 81-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rodriguez-Pascual, Jesus [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiogenesis |
|---|
| Anmerkungen: |
Date Revised 14.03.2024 published: Print Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2174/1875692115666170815161754 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283059877 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283059877 | ||
| 003 | DE-627 | ||
| 005 | 20240314233726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1875692115666170815161754 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1328.xml |
| 035 | |a (DE-627)NLM283059877 | ||
| 035 | |a (NLM)29657584 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rodriguez-Pascual, Jesus |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer |b A Review |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a BACKGROUND: Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body | ||
| 520 | |a CONCLUSION: After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Colorectal cancer | |
| 650 | 4 | |a angiogenesis | |
| 650 | 4 | |a bevacizumab | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a metastatic disease | |
| 700 | 1 | |a Cubillo, Antonio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacogenomics and personalized medicine |d 2008 |g 15(2017), 2 vom: 01. Dez., Seite 81-85 |w (DE-627)NLM187562679 |x 1875-6921 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2017 |g number:2 |g day:01 |g month:12 |g pages:81-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1875692115666170815161754 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2017 |e 2 |b 01 |c 12 |h 81-85 | ||